By Iain Gilbert
Date: Tuesday 13 Aug 2024
(Sharecast News) - Analysts at Berenberg raised their target price on Hikma Pharmaceuticals from 2,000.0p to 2,100.0p on Tuesday following an "impressive" H1 performance.
Hikma reported 10% revenue growth and upgraded guidance for FY24 revenues to 6-8% and core operating profit to $700.0m-730.0m from 4-6% and $660.0m-700.0m, respectively.
Berenberg, which...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news